Table 4. Clinical TNM staging and RECK genotypic frequencies in 135 HCC patients.

Variable	rs10814325			rs16932912			rs11788747			rs10972727
	TT (N = 21)	TC+CC (N = 144)	p value	GG (N = 64)	GA+AA (N = 71)	p value	AA (N = 83)	AG+GG (N = 52)	p value	TT (N = 76)	TA+AA (N = 59)	p value
	n (%)	n (%)		n (%)	n (%)		n (%)	n (%)		n (%)	n (%)
Clinical stage
Stage I/II	12 (57.1%)	72 (63.2%)	0.601	38 (59.4%)	46 (64.8%)	0.517	54 (65.1%)	30 (57.7%)	0.390	49 (64.5%)	35 (59.3%)	0.540
Stage III/IV	9 (49.2%)	42 (36.8%)		26 (40.6%)	25 (35.2%)		29 (34.9%)	22 (42.3%)		27 (35.5%)	24 (40.7%)
Tumor size
≦T2	13 (61.9%)	72 (64.9%)	0.791	41 (64.1%)	46 (64.8%)	0.930	55 (66.3%)	32 (61.5%)	0.577	51 (67.1%)	36 (61.0%)	0.464
>T2	8 (38.1%)	42 (35.1%)		23 (35.9%)	25 (35.2%)		28 (33.7%)	20 (38.5%)		25 (32.9%)	23 (39.0%)
Lymph node metastasis
No	19 (90.5%)	109 (95.6%)	0.298	60 (93.8%)	68 (95.8%)	0.442	79 (95.2%)	49 (94.2%)	0.550	72 (94.7%)	56 (94.9%)	0.639
Yes	2 (9.5%)	5 (4.4%)		4 (6.3%)	3 (4.2%)		4 (4.8%)	3 (5.8%)		4 (5.3%)	3 (5.1%)
Distant metastasis
No	19 (90.5%)	110 (96.5%)	0.235	59 (92.2%)	70 (98.6%)	0.082	83 (100.0%)	46 (88.5%)	0.003*	75 (98.7%)	54 (91.5%)	0.057
Yes	2 (9.5%)	4 (3.5%)		5 (7.8%)	1 (1.4%)		0 (0%)	6 (11.5%)		1 (1.3%)	5 (8.5%)

^* p value<0.05.